Health Blueprint

Back to Longevity News

News summary

Real-World Data from OneOncology Practices Show Tarlatamab Can Be Administered Safely in the Outpatient Community Oncology Setting

Source: PR Newswire • Published: 27 Oct 2026, 19:44

Summarized by Masters of Longevity from PR Newswire.

A 90‑patient retrospective study found mostly low‑grade CRS and ICANS across care models.

Real-World Data from OneOncology Practices Show Tarlatamab Can Be Administered Safely in the Outpatient Community Oncology Setting
Key Takeaways
  • Forty‑six percent of patients experienced cytokine release syndrome.
  • Fourteen percent of patients experienced immune‑effector neurotoxicity.
  • The retrospective cohort has not established causality or selection effects.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickWhat Changes in the Human Hippocampus with Age?A study of 40 postmortem brains maps a midlife shift in immune cells and a wider loss of cellular and genome organisation—but it does not show how to prevent cognitive decline.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickCan Doctors Be Trained for the Longevity Era?A new global survey suggests that healthy longevity medicine education can change how physicians think and talk about ageing. But the evidence also highlights how much work remains before a rapidly growing field becomes routine clinical care.